EN DE
Watch SymBio Pharmaceuticals Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

SymBio Pharmaceuticals Limited (SYMQY) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of SymBio Pharmaceuticals Limited stock $0.37, price $0.47, that is 21.4% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan · ISIN US87150Y1001

SP SymBio Pharmaceuticals Limited logo Thin data Nov 10, 2026

SymBio Pharmaceuticals Limited

SYMQY · US

Expensive (fair value 21% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Revenue last quarter 22% below a year ago. 
Fair value $0.3659 · Overvalued 
Quality 28/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −14.4 %/yr in JPY) 
Negative free cash flow 
Trails peers (0/6) 
Narrow moat 12/100
Thin data 
Estimate⚠ Thinly traded
Watch SymBio Pharmaceuticals Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.98 $0.2805 Fair Value $0.3659 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.2805 – $6.98 · fair‑value band $0.2744 – $0.4574 · the $0.4655 price screens above the $0.3659 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow SymBio Pharmaceuticals in your weekly email

Every Wednesday you see whether SymBio Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally.

Show moreShow less

It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name.

The company was incorporated in 2005 and is based in Minato, Japan.

Stock analysis

SymBio Pharmaceuticals Limited (SYMQY) currently trades at $0.4655, while our estimate is $0.3659, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2744 (bear) to $0.4574 (bull), the price of $0.4655 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

SymBio Pharmaceuticals Limited reported revenue of ¥1.4B in FY2025 versus ¥8.3B in FY2021, a compound −36.2%/yr. Reported net income was −¥5.0B in FY2025.

Key figures

Market cap $35.5M Micro · P/S ratio 0.02 · EPS (TTM) $−0.5600 · Return on equity −3,426% · Return on assets (EBIT) −35.5% (5-year average) · Operating margin −488% · Revenue (TTM) ¥1.1B · Revenue growth (YoY) −22.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 27% below its 52-week high and 66% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −21%, SYMQY screens cheaper than that median.

Fair Value

Bear $0.2744 Fair Value $0.3659 Bull $0.4574
Price $0.4655 · Downside -21.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 2
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 28
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−44.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−48.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
Start year 2020 (pandemic). Over 10 years: −3.4% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−150.9% (2020) → −339.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SYMQY screens overvalued: fair value 21% below the price. Compare with Merck KGaA →

Compare SymBio Pharmaceuticals Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −21.4% · Below median
Profitability
Return on assets −129.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −22.1% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.46× · Priciest 25%
P/S (12 months) 5.36× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $83.82 $113.53 +35% vs SYMQY
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.07 ¥53.04 +10% vs SYMQY
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,880 ₹1,983 +5% vs SYMQY
Haleon plc HLN $9.17 $8.62 −6% vs SYMQY
Merck KGaA MRK €149.60 €108.83 −27% vs SYMQY
Galderma Group GALD CHF 191.40 CHF 111.92 −42% vs SYMQY
Takeda Pharmaceutical Company TAK $21.43 $11.20 −48% vs SYMQY
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs SYMQY
Teva Pharmaceutical Industries Limited TEVA $44.50 $20.74 −53% vs SYMQY
Divi's Laboratories Limited DIVISLAB ₹11,442 ₹1,567 −86% vs SYMQY

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SymBio Pharmaceuticals Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "SymBio Pharmaceuticals Limited Fair Value". https://www.fairvalue-calculator.com/stock/SYMQY

Frequently asked questions

Is SymBio Pharmaceuticals Limited (SYMQY) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.3659 versus the last price from Nov 5, 2026 of $0.4655, about 21% lower (overvalued).
What is the fair value of SYMQY?
Our estimate for SymBio Pharmaceuticals Limited is $0.3659 (as of Nov 10, 2026), built from audited fundamentals. Last price (from Nov 5, 2026): $0.4655.
What is the quality score of SYMQY?
SymBio Pharmaceuticals Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SymBio Pharmaceuticals Limited (SYMQY)?
Our calculated price target is the estimate of $0.3659 (as of Nov 10, 2026). Cautious scenario $0.2744, optimistic scenario $0.4574. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the SymBio Pharmaceuticals Limited stock forecast for 2026?
Our estimate puts fair value at $0.3659, about 21% lower versus the last price from Nov 5, 2026 of $0.4655 (overvalued). Cautious scenario $0.2744, optimistic scenario $0.4574. The calculation is refreshed regularly with new filings.
What is the revenue of SymBio Pharmaceuticals Limited (SYMQY)?
SymBio Pharmaceuticals Limited reported trailing-twelve-month revenue of about ¥1.1B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of SymBio Pharmaceuticals Limited (SYMQY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SymBio Pharmaceuticals Limited it is $0.3659 per share (as of Nov 10, 2026), against a price of $0.4655.
Is SymBio Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SYMQY trades above its calculated fair value: price $0.4655, fair value $0.3659, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYMQY?
No. The price is what the market pays today ($0.4655); the fair value is what the company's own numbers justify ($0.3659). For SymBio Pharmaceuticals Limited the two are $0.0996 per share apart. That gap is exactly why we show both numbers side by side.
How much is SymBio Pharmaceuticals Limited worth?
The market values SymBio Pharmaceuticals Limited at about $35.5M (market capitalisation, as of Nov 10, 2026). Per share that is $0.4655; our models calculate a fair value of $0.3659 per share.
What do the bullish and bearish scenarios say about SYMQY?
Our models span a range for SymBio Pharmaceuticals Limited: cautious scenario $0.2744, base $0.3659, optimistic $0.4574 per share (as of Nov 10, 2026, price $0.4655). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is SYMQY from its 52-week high?
SymBio Pharmaceuticals Limited trades at $0.4655, about 27% below its 52-week high of $0.6370 and 66% above the low of $0.2805 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3659 is for.
Which stocks are comparable to SymBio Pharmaceuticals Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Galderma Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SymBio Pharmaceuticals Limited stock attractive at the current price?
The data as of Nov 10, 2026: price $0.4655, calculated fair value $0.3659 (−21%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. SymBio Pharmaceuticals Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SymBio Pharmaceuticals Limited (SYMQY)?
The latest price we hold is from Nov 5, 2026 and stands at $0.4655. Our estimate is $0.3659, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SymBio Pharmaceuticals Limited right now?
Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SymBio Pharmaceuticals Limited

How large is the market capitalisation of SymBio Pharmaceuticals Limited (SYMQY)?
The market capitalisation of SymBio Pharmaceuticals Limited is $35.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SymBio Pharmaceuticals Limited (SYMQY)?
The price-to-sales ratio of SymBio Pharmaceuticals Limited is 0.02 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SymBio Pharmaceuticals Limited (SYMQY)?
Earnings per share at SymBio Pharmaceuticals Limited are $−0.5600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SymBio Pharmaceuticals Limited (SYMQY)?
The return on equity (ROE) of SymBio Pharmaceuticals Limited is −3,426% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SymBio Pharmaceuticals Limited (SYMQY)?
On an EBIT basis the return on assets of SymBio Pharmaceuticals Limited is −35.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SymBio Pharmaceuticals Limited (SYMQY)?
The operating margin of SymBio Pharmaceuticals Limited is −488% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SymBio Pharmaceuticals Limited (SYMQY)?
Revenue at SymBio Pharmaceuticals Limited is growing −22.1% versus a year earlier (3y avg −48.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SymBio Pharmaceuticals Limited (SYMQY)?
Earnings per share at SymBio Pharmaceuticals Limited are growing −97.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SymBio Pharmaceuticals Limited (SYMQY) generate?
The free cash flow of SymBio Pharmaceuticals Limited is −¥4.8B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SymBio Pharmaceuticals Limited (SYMQY) hold?
SymBio Pharmaceuticals Limited holds more cash than debt, ¥902M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SymBio Pharmaceuticals Limited in the live analysis

One click puts SymBio Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.